User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
The conversation is about using RF microneedling with ExoHealer, along with finasteride and minoxidil, to improve hair thickness and reduce shedding. The user reports noticeable improvements in scalp texture and oiliness, with plans to consider stem cell treatments in the future.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.
Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.
Hair loss treatments ExoFlo and XoFlo use exosomes from stem cells to stimulate hair growth. The user seeks feedback on results from those who tried these treatments.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The user is one month into their FUE treatment and has just undergone PRP treatment at American Mane in Miami. They plan to start using minoxidil and LLT, take xpecia with saw palmetto, and try Exosome from ExoScrt and PRP for better hair growth results.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.
The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.
Exosome treatment for hair loss is being considered, but its effectiveness is questioned. The user is already using finasteride and minoxidil and is contemplating a hair transplant.
The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
Exosomes were used for hair loss treatment, showing results 33 days after the second session. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.